Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3Kγ isoform

Development of novel PI3K inhibitors is an important strategy to overcome their resistance and poor tolerability in clinical trials. The quassinoid family member Brusatol shows specific inhibitory activity against hematologic malignancies. However, the mechanism of its anti-cancer activity is unknow...

Descripción completa

Detalles Bibliográficos
Autores principales: Pei, Yonggang, Hwang, Nicky, Lang, Fengchao, Zhou, Lanlan, Wong, Josiah Hiu-yuen, Singh, Rajnish Kumar, Jha, Hem Chandra, El-Deiry, Wafik S., Du, Yanming, Robertson, Erle S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253423/
https://www.ncbi.nlm.nih.gov/pubmed/32461675
http://dx.doi.org/10.1038/s42003-020-0996-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253423/
https://www.ncbi.nlm.nih.gov/pubmed/32461675
http://dx.doi.org/10.1038/s42003-020-0996-z

Ejemplares similares